Related Experiment Video
Updated: Jun 8, 2025

Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
Published on: February 2, 2024
Does Body Mass Index Affect the Success of Two-Stage Management of Periprosthetic Joint Infection?
Samuel G Raney1, George J Haidukewych2, Matthew J Williamson2
1Division of Adult Reconstruction, Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Background:
Obesity is associated with increased infection risk after primary total joint arthroplasty. In this retrospective cohort analysis, we sought to assess the association between body mass index (BMI) and infection recurrence after two-stage revision total joint arthroplasty for periprosthetic joint infection (PJI).
Methods:
Patients were grouped by BMI (< 30, 30 to 40, and ≥ 40) as non-obese, obese, and morbidly obese, and assessed for associations and timing of PJI reinfection as well as readmissions and complications.
Results:
Following the two-stage revision, PJI reinfections increased from 11.5% in nonobese to 19.0% in obese and 25.9% in morbidly obese patients (P = 0.011). As BMI increased across the three groups, 90-day readmission rates following two-stage PJI revision significantly increased (8.6, 19.7, and 16.7%, respectively (P = 0.042)). The average time to reinfection decreased with obesity tercile (restricted-mean times of 4.5, 4.2, and 3.8 years with non-obese, obese, and morbidly obese, respectively (P = 0.023)).
Conclusions:
The success of PJI management with two-stage arthroplasty is significantly impacted by patient BMI, with morbidly obese subjects having the worst outcomes. Attempts to modify BMI before completion of two-stage PJI treatment should be considered in the morbidly obese given high rates of recurrence.
Insights
Higher body mass index (BMI) correlates with increased risk of periprosthetic joint infection (PJI) recurrence after two-stage revision surgery. Morbidly obese patients face the highest reinfection rates, suggesting BMI modification may improve outcomes.
Area of Science:
- Orthopedic Surgery
- Infectious Disease
- Obesity Medicine
Background:
- Obesity is a known risk factor for complications following primary total joint arthroplasty.
- Periprosthetic joint infection (PJI) is a serious complication requiring revision surgery.
- The impact of varying degrees of obesity on PJI recurrence after two-stage revision is not fully understood.
Purpose of the Study:
- To investigate the association between body mass index (BMI) and infection recurrence after two-stage revision total joint arthroplasty for PJI.
- To analyze the relationship between BMI and reinfection rates, readmissions, and complications in PJI patients undergoing revision surgery.
Main Methods:
- Retrospective cohort analysis of patients undergoing two-stage revision for PJI.
- Patients were stratified into three BMI groups: non-obese (<30), obese (30-40), and morbidly obese (≥40).
- Outcomes assessed included PJI reinfection rates, timing of reinfection, 90-day readmission rates, and other complications.
Main Results:
- PJI reinfection rates significantly increased with BMI: 11.5% (non-obese), 19.0% (obese), and 25.9% (morbidly obese).
- Ninety-day readmission rates after two-stage PJI revision also rose with increasing BMI.
- The average time to reinfection decreased as BMI increased, indicating faster recurrence in more obese patients.
Conclusions:
- Patient BMI significantly impacts the success of PJI management via two-stage arthroplasty.
- Morbidly obese patients exhibit the poorest outcomes, with substantially higher rates of PJI recurrence.
- Considering BMI modification strategies before completing two-stage PJI treatment may be beneficial for morbidly obese individuals to reduce recurrence risk.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Endocarditis III: Medical Management

